Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02034188|
Recruitment Status : Completed
First Posted : January 13, 2014
Last Update Posted : August 10, 2017
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Multiple Sclerosis||Biological: Umbilical cord mesenchymal stem cells||Phase 1 Phase 2|
The proposed study will assess primarily safety and secondary efficacy endpoints of allogeneic umbilical cord mesenchymal stem cells (UC-MSC) administered to 20 patients with MS.
The primary objective of the trial is freedom from treatment associated adverse events at 4,12 and 52 weeks post treatment. Secondary objective will be efficacy as assessed at baseline, week 12 and 52 and will be quantified based on the following: Neurological assessment of the MS functional composite assessment which comprises of Expanded Disability Status Scale (EDSS), the expanded EDSS (Rating Neurologic Impairment in Multiple Sclerosis, the Scripps neurological rating scale (NRS), paced auditory serial addition test (PASAT), the nine-hole peg test, and 25-foot walking time. Short-form 36 (SF-36) quality of life questionnaire and gadolinium enhanced MRI scans of the brain and cervical spinal cord will also be performed at the indicated time points.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis|
|Study Start Date :||January 2014|
|Actual Primary Completion Date :||March 2016|
|Actual Study Completion Date :||March 2016|
|Experimental: Umbilical cord mesenchymal stem cells||
Biological: Umbilical cord mesenchymal stem cells
- Number of participants with adverse events [ Time Frame: 12 months ]
- Number of participants with a change in disability as measured by Expanded Disability Status Scale (EDSS) [ Time Frame: 12 months ]
- Number of participants with a change in neurological impairment as measured by Scripps Neurological Rating Scale [ Time Frame: 12 months ]
- Number of participants with a change in cognitive function as measured by the • Paced Auditory Serial Addition Test (PASAT) [ Time Frame: 12 months ]
- Number of participants with a change in upper extremity function as measured by the Nine Hole Peg Test [ Time Frame: 12 months ]
- Number of participants with a change in mobility and leg function as measured by the 25 foot walking test [ Time Frame: 12 months ]
- Number of participants with a change in quality of life as measured by the Short form 36 (SF-36) quality of life questionnaire [ Time Frame: 12 months ]
- Number of participants experiencing pulmonary edema as measured by 12-lead electrocardiogram (ECG) [ Time Frame: 1 month, 3 months ]
- Number of participants with a change in brain or spinal cord lesions as measured by gadolinium-enhanced magnetic resonance imaging (MRI) [ Time Frame: 12 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 55 Years (Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients willing to sign informed consent and capable of understanding the features of this clinical trial.
- Willing to keep a weekly diary and undergo observation for 12 months
- Non-pregnant patients 18-55 years of age with MS according to the revised McDonald criteria and meeting the Poser criteria for clinically defined MS.
- EDSS scores of 2·0 to 5·5 points assessed at least 3 months after the last acute attack of MS.
- Must have proof of health insurance in country of residence.
- Patients with evidence of active proliferative retinopathy.
- Patients with poorly controlled diabetes mellitus (glycated hemoglobin: HbA1C > 8.5%).
- Patients with renal insufficiency (Creatinine> 2.5) or failure.
- Infection as evidenced by white blood cell (WBC) count of >15,000 k/cumm and/or temperature > 38 Celsius.
- History of organ transplant.
- History of previous or active malignancy, except for localised cutaneous basal or squamous cell carcinoma or carcinoma in situ of the cervix
- Exercise limiting angina ( Canadian Cardiovascular Society Class 3
- Congestive heart failure (New York Heart Association class 3
- Unstable angina
- Acute ST elevation myocardial infarction (MI) within 1month
- Transient ischemic heart attack or stroke within 1 month
- Severe valvular heart disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02034188
|Stem Cell Institute|
|Panama City, Panama|
|Principal Investigator:||Jorge Paz-Rodriguez, MD||Translational Biosciences / Stem Cell Institute|
|Responsible Party:||Translational Biosciences|
|Other Study ID Numbers:||
|First Posted:||January 13, 2014 Key Record Dates|
|Last Update Posted:||August 10, 2017|
|Last Verified:||August 2017|
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Immune System Diseases